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The Benefits of Bioprospecting
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Offers advantage over comparable terrestrial resource:
Superior performance
Better economics
Unprecedented activity in particular application:
Enzymes: new reactivity/new biotransformation









Owner: New England Biolabs
Fuelzyme
Enzyme used in biodiesel production


































Scientific knowledge & data Commercial
‘Potential’ value Actual value
Thomas Vanagt
2001: Derivative synthesis




1996: SynthesisLaboratory tests 
and clinical trials
2010: approval by 
US FDA)
Current sales
Ca US$ 350 M pa
(Usual Royalty 
Rates are 1-3%)
The Marine Pharmaceutical Pipeline
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Pre P-I P-II P-III Clinic
Mainly derived from shallow reef dwelling organisms
Mainly anti-cancer with a few analgesics and antivirals




Balanced benefit sharing must 
consider:
Size and timing of benefits accrued by 
user(s)
Cost and burden of benefit-sharing to 
the user
Burden of benefit-sharing to the 
regulator – institutional cost
Who are the beneficiaries?
How many beneficiaries are there?
Impact of benefit-sharing on the 
beneficiary
Timing of the transaction
Requirements:
Inclusivity of developing states
Facilitated access for the scientific 
community
Legal certainty, predictability and 
stability for industry
Enforceability for the regulator
Mare Geneticum
Access:
Online notification system: OPEN
Free but conditional access
Embargo period
Benefit-Sharing:
Mandatory deposit of material in 
biorepositories
Mandatory sharing of meta data and 
raw data (including GSD)
Possibility of extending embargo period 
in return for a fee
If monetary benefits are requested: at 
the point of commercialization, and not 
negotiated




Scientific knowledge & data Commercial

















Each step may take a significant period
In addition, there may be periods
of inactivity/waiting for a variety
of reasons
Sample and Data Management
Sample and data management from origin to exploitation is possible
Already part of good scientific practice but needs standards & improved data infrastructure
Source: OpenNAPIS, White Point Systems
Geographic Information System











tested in 10 
assays
1 10 40 320 3200
25 Compounds
Total 3596 datapoints – for 1 sample
& Genetic Sequence Data
Real World Example
Network Analysis of PharmaSea Dataset (150,000 datapoints)
shows complexity of data
















(Location, metadata, species etc)
Share Materials
Researchers accessing material


















IT Solutions (e.g. Blockchain) 




Prof. Pete Edwards, Computing, Aberdeen University
Decentralised/Minimal traceability requirement
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